Biotechnology
Novavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the European Union to Adolescents (Ages 12-17)
* If granted, Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) would be the first protein-based option for adolescents aged 12-17 years inEurope GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializi...
2022-03-31 18:00
2808
Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
Novel preventative AT-100 offers potential to reduce incidence and severity of serious respiratory disease BPD, improving outcomes in very preterm infants MARIETTA, Ga., March 31, 2022 /PRNewswire/ -- Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biolog...
2022-03-31 17:00
2205
CBC Group-backed Hasten Biopharma successfully completes acquisition of five cardiovascular and metabolism drugs from Takeda
* CBC Group continues to expand its global healthcare ecosystem to fulfil unmet medical needs * Hasten fast-tracks transformative medicines for patients in China SHANGHAI, March 31, 2022 /PRNewswire/ -- Hasten Biopharmaceutic Co., Ltd (China) ("Hasten") today announced that it has acquired a ...
2022-03-31 15:05
1707
CStone announces first patient enrollment in the U.S. in the Phase 1 clinical trial of CS5001, a potential global best-in-class ROR1-targeting ADC
* Commencement of the first-in-human clinical trial of CS5001 marks another key milestone for CStone's Pipeline 2.0 * Global development of CS5001 is conducted in the form of a multi-regional clinical trial, with sites initiated in the US andAustralia, and an IND application accepted by the ...
2022-03-31 08:02
3088
LifeTech Scientific Corporation（1302.HK） Announces 2021 Annual Results
Excluding certain non-recurring items, the net profit attributable to owners of the Company increased by 76.8% to RMB 324.0million SHENZHEN, China, March 30, 2022 /PRNewswire/ -- LifeTech Scientific Corporation (LifeTech, 1302.HK), a leading company specialized in minimally invasive interventio...
2022-03-31 03:27
3019
Symbiance announces the launch of SimpleStats, an application for statistical analysis and reporting of clinical data
PRINCTON, N.J., March 30, 2022 /PRNewswire/ -- SimpleStats (www.SimpleStats.ai) is designed to help Pharmaceutical/Biotech industries to automate statistical analysis and reporting of clinical data! Symbiance announced the launch of its Artificial Intelligence (AI) powered product SimpleStats. T...
2022-03-30 21:00
1477
GenScript Receives "Best Contract Development and Manufacturing Organization Award" For the Third Time in a Row
SINGAPORE, March 30, 2022 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) receives the "Best Contract Development and Manufacturing Organization Award" on the Asia Pacific Bioprocessing Excellence Awards 2022. This marks the third consecutive year of GenScript bag...
2022-03-30 17:30
4157
BioVaxys Expands Cancer Vaccine Platform
BVX-0922 to Target Colorectal Cancer Under Investigator-Sponsored IND VANCOUVER, BC, March 30, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today the expansion of its cancer vaccine platform with BVX-0922, its autolog...
2022-03-30 16:02
3215
Qiming's Portfolio Company Rendu Biotechnology Lists on STAR Market
SHANGHAI, March 30, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company Rendu Biotechnology (SESH: 688193), a leader in RNA molecular diagnostics inChina, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange. The issue price is...
2022-03-30 10:22
2883
Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes
* This study is the third ATG-016 study to be conducted in China. * Study highlights Antengene's robust SINE programs. SHANGHAI and HONG KONG, March 30, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutic...
2022-03-30 09:00
2182
RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines
GAITHERSBURG, Md., March 30, 2022 /PRNewswire/ -- RNAimmune, Inc. (the "Company " or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today that is has secured an approximatelyUS$27 million Series A round of fina...
2022-03-30 08:31
2173
Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
DURHAM, N.C. and BEIJING, March 30, 2022 /PRNewswire/ -- Brii Biosciences
Limited
2022-03-30 08:05
2767
Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology
- Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referred to as PYX-106), a fully human anti-Siglec-15 monoclonal antibody - Biosion earns a $10 million upfront license fee; additional milestone payments and royalties on commercial sales to be earned up...
2022-03-29 23:00
1831
CellOrigin Closed a New Round of Investment to Jump-start its iPSC Immune Cell Therapy Products Toward Clinics
HANGZHOU, China, March 29, 2022 /PRNewswire/ -- On Mar.21, 2022, CellOrigin Inc, a biotech company focusing on iPSC-derived immune cell therapies, announced it secured a new round of investment of ~100 million RMB from Jifeng Ventures, Kunlun Capital, Yinxinggu Capital and Efung Capital. CellOri...
2022-03-29 20:50
1421
Laekna Therapeutics Appoints Jeff Porter, Ph.D. as Chairman of Scientific Advisory Board
SHANGHAI and WARREN, N.J., March 29, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage global biotechnology company，announced today the appointment of Jeff Porter, Ph.D. as the Chairman of its Scientific Advisory Board (SAB). Dr. Porter has over 25 years of global R&D leadership and strat...
2022-03-29 20:00
1451
New Video Series "PSMA PET/CT TODAY" Discusses the Future of Prostate Cancer Care with Leading Experts
MELBOURNE, Australia and INDIANAPOLIS, March 29, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the launch of PSMA PET/CT[1] Today, a five-part video series, featuring leading theranostics experts, on the role of advanced diagnostic imaging in pr...
2022-03-29 19:00
1353
Samsung Biologics holds 11th Annual General Meeting of Shareholders
INCHEON, South Korea, March 28, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), hosted its 11th Annual General Meeting of Shareholders (AGM)today. Five matters were presented and approved unanimously at this ...
2022-03-29 09:42
1927
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue Tablets to the Philippines
- From Last February to mid-March, NDA has been submitted to each country sequentially - Daewoong Pharmaceutical expects to strengthen its global business in key markets of ASEAN countries by obtaining marketing authorization in foreign countries with its branch offices SEOUL, South Korea, Marc...
2022-03-29 09:00
2319
ILC Dover Announces Liquid Single-Use Bioprocessing Bags for Rapidly Growing Biotherapeutics and Cell & Gene Therapy Markets
NEWARK, Del., March 29, 2022 /PRNewswire/ -- ILC Dover LP ("ILC Dover" or the "Company"), specializing in innovative single-use solutions for biotherapeutics and pharmaceutical processing, announced its launch of liquid single-use bioprocessing bags, representing the first of many new products fo...
2022-03-29 05:11
1358
Viva Biotech Announced 2021 Annual Results: Revenue Increased by 201.9% YoY, CRO Business Revenue Maintained Rapid Growth with an Increase of 68.7%
Financial Highlights of the year ended December 31, 2021: * Revenue amounted to RMB2,104.1 million, representing a year-on-year (YoY) increase of 201.9% * Gross profit amounted to RMB651.0 million, representing a YoY increase of 113.5% * Adjusted Non-IFRS net profit amounted to RMB352.5 mil...
2022-03-29 01:01
2558
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9273
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7751